- Home
- JNJ
as 10-07-2025 3:28pm EST
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as Johnson & Johnson JNJ prepares to release earnings report on 14 Oct 2025.
| Founded: | 1886 | Country: | United States |
| Employees: | N/A | City: | NEW BRUNSWICK |
| Market Cap: | 408.0B | IPO Year: | 1944 |
| Target Price: | $187.38 | AVG Volume (30 days): | 8.8M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 9.33 | EPS Growth: | -39.59 |
| 52 Week Low/High: | $140.68 - $189.92 | Next Earning Date: | 10-14-2025 |
| Revenue: | $90,627,000,000 | Revenue Growth: | 4.68% |
| Revenue Growth (this year): | 6.23% | Revenue Growth (next year): | 4.61% |
Stock Insider Trading Activity of Johnson & Johnson (JNJ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Taubert Jennifer L | JNJ | EVP, WWC. Innovative Medicine | Sep 4 '25 | Sell | $177.81 | 56,471 | $10,040,882.63 | 178,013.001 | |
| Duato Joaquin | JNJ | CEO and Chairman of the Board | Aug 22 '25 | Sell | $179.21 | 125,824 | $22,548,654.81 | 275,967 | |
| Wolk Joseph J | JNJ | Exec VP, CFO | Aug 15 '25 | Sell | $176.91 | 16,820 | $2,975,570.69 | 14,000 |
Latest Johnson & Johnson News
JNJ Breaking Stock News: Dive into JNJ Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Prudential Financial (PRU): Assessing Valuation as Fundamental Challenges Draw Renewed Investor Scrutiny
MT Newswires
a day ago
Johnson & Johnson Says Disposable Contact Lens Product Shows Higher End-of-Day Comfort
PR Newswire
a day ago
TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
PR Newswire
a day ago
Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill
PR Newswire
a day ago
Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses
MT Newswires
a day ago
Citigroup Adjusts Price Target on Johnson & Johnson to $213 From $200, Maintains Buy Rating
Motley Fool
a day ago
1 Reason I'm Watching Intuitive Surgical Stock in 2026
Zacks
2 days ago
Top Analyst Reports for Microsoft, Amazon.com & Johnson & Johnson
Compare JNJ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JNJ Johnson & Johnson - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.